Drug comparison
Retatrutide vs semaglutide
Semaglutide’s longer clinical history makes this comparison more interesting than a count of receptor targets.
Molecular activity
Semaglutide activates GLP-1 receptors. Retatrutide also activates GIP and glucagon receptors. The comparative review of incretin-based agents describes these approaches alongside their reported weight-loss findings.
The retatrutide receptor study used structural methods and cell assays to show engagement at all three targets. The activities differed relative to the natural hormones. Those experiments help explain the design; clinical outcomes determine what the design achieves in people.
I’m suspicious of treating an extra receptor as an automatic improvement. The addition has to earn its value through benefits, tolerability and outcomes over time.
Weight-loss results
The retatrutide phase 2 obesity trial found 24.2% mean weight loss in the 12 mg group at 48 weeks, against 2.1% for placebo. The semaglutide obesity evidence includes a trial reporting about 14.9% at 68 weeks, against 2.4% for placebo, using 2.4 mg.
Those are separate trials. The populations, observation periods and stages of development differ. The review comparing the agents supplies context for retatrutide’s large result, while leaving the direct clinical comparison unresolved.
The retatrutide figure is impressive enough for me to take it seriously while reserving a verdict on the overall outcome. A sustained effect on health calls for more than a weight endpoint.
Cardiovascular evidence
Semaglutide is approved for type 2 diabetes and obesity and has longer follow-up, including cardiovascular studies. Retatrutide remains unapproved in the mid-2026 account here, with dedicated longer-term outcomes work ongoing.
The cardiometabolic review discusses the prospect that larger weight and metabolic changes with multi-receptor agonists will translate into cardiovascular benefit. Its expectation is a reason to follow the trials, rather than a cardiovascular result for retatrutide.
I give semaglutide credit for that accumulated clinical history. Retatrutide’s chemical persistence and its evidential history run on different scales.
Liver results and stopping treatment
The retatrutide liver-fat substudy showed an 82.4% relative reduction at week 24 in the 12 mg group; 86% of that group reached liver fat below 5%. The study involved 98 participants with overweight or obesity and excess liver fat, without type 2 diabetes. It was not a direct semaglutide comparison.
The review of treatment discontinuation and weight regain describes a further issue for this drug class. Benefits during treatment and persistence after treatment require separate evidence. I’d like the latter question to become as familiar as the headline percentage.
The retatrutide chemistry page returns to what a six-day half-life can actually explain, and the tirzepatide comparison follows the planned direct trial.